Skip to content
OpenCapital
Get started

ArriVent BioPharma, Inc. AVBP Net interest and investment income (loss)

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.49B+62.1%
Enterprise value$1.43B+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0×0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s net interest and investment income (loss).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s net interest and investment income (loss)?
ArriVent BioPharma, Inc. (AVBP) reported net interest and investment income (loss) of $2.79M in Q1 2026.
How has ArriVent BioPharma, Inc.'s net interest and investment income (loss) changed year-over-year?
ArriVent BioPharma, Inc.'s net interest and investment income (loss) increased by 17.0% year-over-year, from $2.39M to $2.79M.
What is the long-term trend for ArriVent BioPharma, Inc.'s net interest and investment income (loss)?
Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s net interest and investment income (loss) has grown at a 46.1% compound annual growth rate (CAGR), from $5.26M to $11.23M.